Advances In Diagnosis And Orphan Drugs Will Open New Horizons
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
16 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$30.00
42.3% undervalued intrinsic discount15 Aug
US$17.30
1Y
282.7%7D
5.7%